Atlantic Therapeutics, a company out of Galway, Ireland, will soon be releasing its INNOVO transcutaneous electrical stimulator to treat stress urinary incontinence in women. The device was FDA approved late last year as the first transcutaneous stimulator with such an indication. It delivers electric current through the body toward muscles that control the pelvic floor, which in turn can help maintain continence.
The technology provides women a non-invasive option that, in a clinical trial, demonstrated that 87% of women were dry or nearly so after a three month treatment. 80% of the women studied had results after only a month or therapy.
“Many people find that SUI gets in the way of their daily and social activities, and INNOVO® is a breakthrough treatment option that can provide relief for millions of women who are living with the burden of incontinence,” said Gordie Nye, Chairman of Atlantic Therapeutics, in a recent announcement. “We are excited to be showcasing our new wearable product here in the US after a successful track record in Europe and sharing it with the professional community at these important meetings.”
Atlantic Therapeutics is not quite yet making INNOVO available, initially focusing on introducing clinicians to the technology at the ongoing 2019 American College of Physicians (ACP) Internal Medicine Meeting in Philadelphia and next month at the 2019 American College of Obstetricians and Gynecology (ACOG) Annual Meeting in Nashville.
Product page: INNOVO…